CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Insulin resistance, dyslipidaemia and obesity are the major cardiometabolic risk factors contributing to the development of type 2 diabetes and cardiovascular disease (CVD). Owing to the increasing prevalence of obesity, type 2 diabetes, and CVD, new and effective pharmacologic therapies are urgently needed. In this regard, the endogenous cannabinoid system (ECS), a neuromodulatory system involved in the regulation of various aspects of energy balance and eating behaviour through central and peripheral mechanisms, may present the potential to meet this need. In the central nervous system (CNS), cannabinoid type 1 (CB1) receptors and their respective ligands, the endocannabinoids, have a significant role in the modulation of food intake and motivation to consume palatable food. CB1 receptors have also been found in organs involved in the regulation of metabolic homeostasis, such as liver, white adipose tissue, muscle and pancreas. Dysregulation of the ECS has been associated with the development of dyslipidaemia, glucose intolerance, and obesity, and CB1 receptor blockade may have a role in ameliorating these metabolic abnormalities. Thus, pharmacologic options targeting the ECS may provide a novel, effective approach to the prevention and management of CVD, type 2 diabetes and obesity. Copyright © 2007 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“Shortly thereafter, a second CB receptor, identified as cannabinoid type 2 (CB2), was described and cloned [12].”
BackgroundStructure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354 · cited 14×
“C-reactive protein is an acutephase protein that is considered a marker of inflammation and a predictive indicator of CVD [117].”
BackgroundInfluentialYamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 1×
“named 2-arachidonoyl glycerol (2-AG) [36].”
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Mechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159 · cited 1×
“In the central nervous system (CNS), the CB1 receptor is highly expressed in the forebrain, basal ganglia, cerebellum, hippocampus and cerebral cortex [22,23].”
BackgroundThe molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 1×
“grade manner by binding to pre-synaptic CB1 receptors (see reviews [20,21,40]).”
BackgroundLeptin-regulated endocannabinoids are involved in maintaining food intake
Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., et al. (2001) · Nature · doi:10.1038/35071088 · Cited by 1,559 · cited 4×
“leptin, CCK, ghrelin) might be causally linked to dysregulation of the ECS [65,82,91].”
BackgroundMethodInfluentialIdentification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · cited 3×
“mRNA and plasma levels of adiponectin observed after treatment with CB1 receptor antagonists [30,106,110].”
BackgroundBrain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373 · cited 1×
“[41,42] and their specific localization provides further”
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293 · cited 1×
“Several inhibitors of anandamide cellular re-uptake or transport and of anandamide hydrolysis have also been identified, presenting multiple pharmacologic opportunities to affect the ECS [55,56].”
BackgroundAdiponectin Expression From Human Adipose Tissue
Kern, P. A., Di Gregorio, G. B., Lu, T., Rassouli, N., & Ranganathan, G. (2003) · Diabetes · doi:10.2337/diabetes.52.7.1779 · Cited by 875 · cited 1×
“Plasma C-reactive protein levels are positively correlated and adiponectin levels are negatively correlated with increasing body weight and fat mass [118,119].”
BackgroundActivation of the peripheral endocannabinoid system in human obesity
Engeli, S., Böhnke, J., Feldpausch, M., Gorzelniak, K., Janke, J., Bátkai, S., Pacher, P., Harvey-White, J., Luft, F. C., Sharma, A. M., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2838 · Cited by 686 · cited 2×
“found that plasma anandamide and 2-AG levels were significantly elevated in obese women compared with lean women [98].”
BackgroundAdiponectin: action, regulation and association to insulin sensitivity
Lihn, A. S., Pedersen, S. B., & Richelsen, B. (2005) · Obesity Reviews · doi:10.1111/j.1467-789x.2005.00159.x · Cited by 660
Eyre, H., Kahn, R., Robertson, R. M., the ACS/ADA/AHA Collaborative Writing Committee, ACS/ADA/AHA Collaborative Writing Committee Members, Clark, N. G., Doyle, C., Hong, Y., Gansler, T., Glynn, T., et al. (2004) · Circulation · doi:10.1161/01.cir.0000133321.00456.00 · Cited by 542
Weight Loss Reduces C-Reactive Protein Levels in Obese Postmenopausal Women
Tchernof, A., Nolan, A., Sites, C. K., Ades, P. A., & Poehlman, E. T. (2002) · Circulation · doi:10.1161/hc0502.103331 · Cited by 541
Endocannabinoid signaling system and brain reward: emphasis on dopamine
GARDNER, E. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.032 · Cited by 387
Chiang, K. P. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh216 · Cited by 278
Gatley, S. J., Gifford, A. N., Volkow, N. D., Lan, R., & Makriyannis, A. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00279-8 · Cited by 252 · cited 1×
“Among the synthetic antagonists, SR 141 716 [52], AM 251 [53] and AM 281 [54] are specific for CB1 receptors.”
BackgroundCôté, M., Mauriège, P., Bergeron, J., Alméras, N., Tremblay, A., Lemieux, I., & Després, J.-P. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1711 · Cited by 230 · cited 1×
“adiponectin levels are negatively correlated to visceral obesity [114], a condition in which the ECS results more activated [97].”
Background
Cited by
Targeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
Cannabinoid Receptors: Where They are and What They do
Mackie, K. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01671.x · Cited by 638
Hirvonen, J., Goodwin, R. S., Li, C.-T., Terry, G. E., Zoghbi, S. S., Morse, C., Pike, V. W., Volkow, N. D., Huestis, M. A., & Innis, R. B. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.82 · Cited by 587
Nissen, S. E., Nicholls, S. J., Wolski, K., Rodés-Cabau, J., Cannon, C. P., Deanfield, J. E., Després, J.-P., Kastelein, J. J. P., Steinhubl, S. R., Kapadia, S., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1547 · Cited by 403
Scheen, A. J. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01681.x · Cited by 68
Metadata
- Authors
- Cota, D.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2007-08-07
- Volume
- 23
- Issue
- 7
- Pages
- 507-517
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W1975317880
- Cited by
- 124
- References
- 26
- FWCI
- 7.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.